SUCRAID (sacrosidase)

Self-Administration – oral solution

Diagnosis considered for coverage:
  • Congenital Sucrase-Isomaltase Deficiency (CSID): Indicated as oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
Coverage Criteria:

 

For diagnosis of CSID:

  • Diagnosis of sucrase deficiency (which is part of congenital sucrose-isomaltase deficiency [CSID]); AND
  • Disease is confirmed by ONE of the following:
    • Disaccharidase assay via a small bowel biopsy 
    • Carbon -13 sucrose breath test 
    • Molecular genetic testing confirms mutation in the SI gene 
    • Stool pH less than 6, an increase in breath hydrogen of greater than 10 parts-per-million (ppm) when challenged with sucrose after fasting and a negative lactose breath test; AND 
  • Prescribed by or in consultation with a gastroenterologist or geneticist
Reauthorization Criteria: 

 

For diagnosis of CSID:

  • Patient demonstrates positive clinical response to therapy (e.g., decrease in symptoms of abdominal pain, cramps, bloating or gas; decrease in number and frequency of stools per day)
Dosing:
  • Patients weighing 15 kg and less: 
    • The recommended dosage is 1 mL (8,500 International Units) administered orally with each meal or snack
  • Patients weighing more than 15 kg: 
    • The recommended dosage is 2 mL (17,000 International Units) administered orally with each meal or snack
Coverage Duration:
  • Initial: 12 months
  • Reauthorization: 24 months
Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Additional Information: 
  • Patients with CSID cannot metabolize sucrose or starch, and they experience symptoms such as diarrhea, abdominal pain, bloating, and abdominal distention from the excessive fermentation of undigested carbohydrates. 
  • Sucraid does not enable the metabolism of starch, so CSID patients still need to avoid starch in order to avoid digestive problems while taking Sucraid.
  • No other product has been approved by the FDA to treat CSID. In some CSID patients, the disease can be managed by diet, by avoiding sucrose and sucrose-containing foods and medicines, as well as by avoiding starch.
Policy Updates:
  • 06/01/2024 – New policy for Sucraid approved by WHA P&T Committee. (P&T, 05/21/2024)
References:
  1. Sucraid Prescribing Information. QOL Medical, LLC. Vero Beach, FL. May 2022. 
  2. Congenital Sucrase-Isomaltase Deficiency (CSID). International Foundation for Gastrointestinal Disorders. Available at https://iffgd.org/gi-disorders/congenital-sucrase-isomaltase-deficiency-csid/. Accessed October 24, 2022. 
  3. Smith, H., Romero, B., et al. The patient journey to diagnosis and treatment of congenital sucrase-isomaltase deficiency. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298246/. Accessed October 24, 2022. 
  4. Chey, W., Cash, B., et al. Congenital Sucrase-Isomaltase Deficiency: What, When, and How? Gastroenterology and Hepatology. October 2020. Available at https://www.gastroenterologyandhepatology.net/files/2020/10/gh1020sup5-1.pdf. Accessed October 24, 2022.
     

Last review date: June 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone